Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 6 minute read Pharma Industry News Why Imugene is using a virus to “mark” tumors for CAR-T attack—and what JW Therapeutics brings to the table Find out how Imugene and JW Therapeutics plan to make solid tumors respond to CD19 CAR-T therapy using an oncolytic virus strategy. byVenkateshNovember 28, 2025